EWTX.US Edgewise Therapeutics Inc

Healthcare Biotechnology USA Stocks
45.93 USD
Close of Nov 14, 2026
19.76 48.78
Market cap
USD 5.03B
P/E
5.5x
P/B
3.07x
ROE
86.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EWTX.US undervalued?

Graham number
Price45.93
Graham value53.09
Discount13.5%

EWTX.US trades 13.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Edgewise Therapeutics Inc fundamental analysis

No fundamental analysis for Edgewise Therapeutics Inc yet.

Edgewise Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Edgewise Therapeutics Inc

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyo…

Full company profile